Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostrox + lenvatinib vs lenvatinib in second-line advanced hepatocellular carcinoma after combination immunotherapy
KCT0011819Phase 2Not yet recruiting
- Sponsor
- Medivir
- Start
- Apr 2026
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Fostrox + lenvatinib with Lenvatinib monotherapy (2 arms). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Fostroxacitabine bralpamidelenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0011819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011819.